Follow the H. Lundbeck A/S stock price and the full management transaction log of the company, a listed equity based in Denmark. Shares are quoted on the DK market, under the authority of Finanstilsynet DK. Operating in the Health Care sector, H. Lundbeck A/S has recorded 63 insider filings. Market capitalisation: €42.1bn. The latest transaction was filed on 16 February 2024 (Purchase). All data is free.
63
Insider Decl.
n/a
Thresholds
€923,063
30 ops.
Buy Volume
€18m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate H. Lundbeck A/S Buy (bullish), based on 12 analysts. Average price target: DKK 47.88.
13Σ signal
Buys €923,063€18m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 1,923 of 28,958 companies
77.1
score / 100
Value
79
Quality
75
FCF yld12%
Earn yld7.6%
EV/EBITDA7.8x
ROE15%
Gross mgn83%
Net mgn13%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
42,478 shares@ DKK 126.660.0018% mcap2.1% of flowShareH. Lundbeck A/S (the subscribed for shares will be registered onDK:724717
25 of 63 declarations
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company focused on developing treatments for psychiatric and neurological disorders. It emphasizes innovation in medications for conditions such as depression and schizophrenia.